Latest news

Thumbnail image for Novartis links with NHS Cancer Vanguard sites

Novartis links with NHS Cancer Vanguard sites

Swiss drug giant Novartis has announced the launch of two new joint working projects with national Cancer Vanguard sites, which aim to determine novel ways of boosting patient care pathways and access to services.

21st March 2018

Thumbnail image for Charity forms Alzheimer’s disease taskforce

Charity forms Alzheimer’s disease taskforce

Alzheimer’s Research UK is calling on the NHS and the pharma industry to join its new taskforce to ensure people with dementia can access future treatments without unnecessary delay.

21st March 2018

Thumbnail image for Skin conditions cost NHS £723m a year

Skin conditions cost NHS £723m a year

New research shows that more than three million primary care hours are spent on skin conditions, at a cost to the NHS of £723 million each year.

21st March 2018

Thumbnail image for NICE rejects rare eye disease drug

NICE rejects rare eye disease drug

Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.

20th March 2018

Thumbnail image for Performance on A&E target slips further

Performance on A&E target slips further

NHS hospital performance against the four-hour A&E target stood at just 74.96 percent, well under the 95 percent target, for the week ending March 11th, show the most recent data from the Royal College of Emergency Medicine’s Winter Flow Project.

19th March 2018

Thumbnail image for Coeliac UK launches new research fund and appeal

Coeliac UK launches new research fund and appeal

Coeliac UK has launched a new research fund and fundraising appeal that aims to raise £5 million to improve understanding and management of coeliac disease and gluten related autoimmune conditions.

19th March 2018

Thumbnail image for US nod for CSL Behring’s Hizentra

US nod for CSL Behring’s Hizentra

US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.

19th March 2018

Previous  --   3 4 5 6 7 8 9 10 11 12   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download